scholarly journals P1-225: FATTY ACID METABOLISM IN CEREBROSPINAL FLUID FRACTIONS CAN DIFFERENTIATE PRE-SYMPTOMATIC FROM SYMPTOMATIC ALZHEIMER'S DISEASE

2019 ◽  
Vol 15 ◽  
pp. P321-P322
Author(s):  
Alfred N. Fonteh ◽  
Matthew Cipolla ◽  
Austin Lee ◽  
Jairong Chiang ◽  
Xianghong Arakaki ◽  
...  
2017 ◽  
Vol 9 (1) ◽  
Author(s):  
Daniel Daugherty ◽  
Joshua Goldberg ◽  
Wolfgang Fischer ◽  
Richard Dargusch ◽  
Pamela Maher ◽  
...  

2008 ◽  
Vol 29 (3) ◽  
pp. 478-480 ◽  
Author(s):  
Francesco Panza ◽  
Cristiano Capurso ◽  
Alessia D’Introno ◽  
Anna M. Colacicco ◽  
Antonio Capurso ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e100519 ◽  
Author(s):  
Alfred N. Fonteh ◽  
Matthew Cipolla ◽  
Jiarong Chiang ◽  
Xianghong Arakaki ◽  
Michael G. Harrington

2020 ◽  
Vol 21 (24) ◽  
pp. 9521
Author(s):  
Fanny Eysert ◽  
Paula Fernanda Kinoshita ◽  
Arnaud Mary ◽  
Loan Vaillant-Beuchot ◽  
Frédéric Checler ◽  
...  

Alzheimer’s disease (AD) is a multifactorial neurodegenerative pathology characterized by a progressive decline of cognitive functions. Alteration of various signaling cascades affecting distinct subcellular compartment functions and their communication likely contribute to AD progression. Among others, the alteration of the physical association between the endoplasmic reticulum (ER) and mitochondria, also referred as mitochondria-associated membranes (MAMs), impacts various cellular housekeeping functions such as phospholipids-, glucose-, cholesterol-, and fatty-acid-metabolism, as well as calcium signaling, which are all altered in AD. Our review describes the physical and functional proteome crosstalk between the ER and mitochondria and highlights the contribution of distinct molecular components of MAMs to mitochondrial and ER dysfunctions in AD progression. We also discuss potential strategies targeting MAMs to improve mitochondria and ER functions in AD.


SLEEP ◽  
2020 ◽  
Vol 43 (11) ◽  
Author(s):  
Mihoko Shimada ◽  
Taku Miyagawa ◽  
Tohru Kodama ◽  
Hiromi Toyoda ◽  
Katsushi Tokunaga ◽  
...  

Abstract Narcolepsy type 1 (NT1) is a hypersomnia characterized by excessive daytime sleepiness and cataplexy. Inappropriate regulation of fatty acid metabolism has been suggested to be involved in the pathophysiology of NT1, but the detailed mechanisms remain uncertain. Here we performed a metabolomic analysis of cerebrospinal fluid samples from 14 NT1 and 17 control subjects using a novel capillary electrophoresis coupled with Fourier transform mass spectrometry. A total of 268 metabolites were identified and the amount of histidine was the most significantly increased in NT1 patients (p = 4.0 × 10–4). Validation analysis using high-performance liquid chromatography (HPLC) including independent replication samples also identified the association of histidine (p = 2.02 × 10–3). Further, levels of histamine, which is synthesized from histidine, were also examined using HPLC and were found to be significantly decreased in NT1 patients (p = 6.12 × 10–4). Pathway analysis with nominally significant metabolites identified several pathways related to the metabolism of glycogenic amino acids, suggesting that glycogenesis is enhanced in NT1 as a compensatory mechanism for fatty acid metabolism. We performed further exploratory analysis, searching for metabolites associated with sleep variables from polysomnography and the multiple sleep latency test. As a result, 5′-deoxy-5′-methylthioadenosine showed a significant association with apnea–hypopnea index (p = 2.66 ×10–6). Moreover, gamma aminobutyric acid displayed a negative correlation with rapid eye movement sleep latency (REML), and thus might represent an intriguing target for future studies to elucidate how the controlling circuit of REM sleep is associated with abnormally short REML in NT1.


2021 ◽  
Vol 7 (1) ◽  
pp. 44-55
Author(s):  
Lu Pan ◽  
Ya-Nan Ou ◽  
Lin Tan ◽  
Lan Tan ◽  
Jin-Tai Yu

Objective This study aims to investigate whether the heart fatty acid‐binding protein (HFABP) in the cerebrospinal fluid (CSF) was a potential predictive biomarker for Alzheimer’s disease (AD). Methods We evaluated the associations of CSF HFABP levels with core biomarkers, cognition, and brain structure in a sample population ( n = 302) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Multiple linear regression and mixed‐effects models were employed in the analyses. AD progression was assessed using the Kaplan–Meier survival analysis. Results CSF HFABP was higher in patients with mild cognitive impairment and AD than the normal controls ( p < 0.001) and was particularly higher in those with amyloid‐β (Aβ) pathologic features. CSF HFABP was associated with higher baseline CSF t‐tau ( p < 0.001), CSF p‐tau ( p < 0.001), and CSF t‐tau/Aβ42 and CSF p‐tau/Aβ42 ( p < 0.01). Moreover, CSF HFABP was found to play predictive roles in hippocampal atrophy ( p < 0.01), cognitive decline ( p < 0.05), and the risk of AD ( p < 0.001). Conclusion Our findings suggest that CSF HFABP can be a predictive biomarker of AD.


2013 ◽  
Vol 36 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Gerd Faxén-Irving ◽  
Yvonne Freund-Levi ◽  
Maria Eriksdotter-Jönhagen ◽  
Hans Basun ◽  
Erik Hjorth ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document